Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Dose-escalation and Dose-expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SY-9453 in Patients With Advanced Solid Tumors

NCT07469982 is registered in ClinicalTrials.gov with Shouyao Holdings (Beijing) Co. LTD as lead sponsor.

NCT NCT07469982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07469982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Dose-escalation and Dose-expansion Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SY-9453 in Patients With Advanced Solid Tumors
Lead sponsor
Shouyao Holdings (Beijing) Co. LTD
Phase
Phase 1
Overall status
Recruiting
Start date
March 12, 2026
Completion date
February 28, 2029
Enrollment
122 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors with homozygous mtap deletion